ArticlePathogens (Basel, Switzerland)2023
Dissemination of Clinical
Article in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Genetic Diversity and Hospital Circulation of Opportunistic Pathogens in COVID-19 ICUs: Whole-Genome Sequencing Data.Pathogens (Basel, Switzerland) · 2026Article
- Antimicrobial resistance trends among dominant pathogens in six clinical departments of the Fourth Affiliated Hospital of Guangxi Medical University, 2020-2024.Frontiers in public health · 2026Article
- Acinetobacter baumannii utilizes a novel protective factor to combat desiccation-induced oxidative stress.PloS one · 2026Article
- Emerging virulent clones of community-onset Acinetobacter baumannii in Taiwan.Tropical medicine and health · 2025Article
- Genetic Characteristics ofPathogens (Basel, Switzerland) · 2025Article
- The Impact of COVID-19 on the Epidemiology of Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- Carbapenem-resistant bacteria in the environment.Arhiv za higijenu rada i toksikologiju · 2025Review
- A chionodracine-derived peptide, KHS-Cnd, as an anti-virulence agent against multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- International Clones of High Risk of Acinetobacter Baumannii-Definitions, History, Properties and Perspectives.Microorganisms · 2023Review
- Changes in Antibiotic Resistance ofJournal of clinical medicine · 2023Article
- The Dark Side of Nosocomial Infections in Critically Ill COVID-19 Patients.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to find the source of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.